Key Drivers
- Strong Liquidity
- Low Leverage
- Margin Compression
AIAI Summary
InMode is a cash-rich turnaround rather than a straightforward value compounder: upside depends on Morpheus8-led revenue recovery restoring operating leverage, while continued margin erosion could turn its low multiple into a prolonged value trap; investors should wait for sequential sales growth and margin stabilization before underwriting a re-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Low Leverage
- •Margin Compression
INMD offers strong liquidity, minimal leverage, positive cash flow, and modest valuation, but worsening margins and operating efficiency warrant close monitoring.
Price Behavior
Key Price Behavior Insights:
- •Falling short-term trend
- •Support under pressure
- •Oversold RSI
INMD is bearish over the last month, trading below its average with support at $14.35; watch for a break lower or a rebound above $14.54–$14.58.
Selling accelerated from $14.87 to $14.35 in three trading days
Sentiment & News
Key News Insights:
- •Technical breakout
- •Product innovation
- •Growth tailwinds
InMode's 200-day breakout, Morpheus8 Cool launch, and aesthetic-medicine growth tailwinds signal improving momentum despite elevated volatility.
The news is moderately positive for InMode, though its high beta may amplify price swings
Similar Companies in Healthcare
Other companies in the same sector with AI ratings